154848-44-9Relevant articles and documents
BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA
-
Page/Page column 82; 83, (2018/06/01)
The invention relates to bimesogenic compounds of formula Iwherein R 11 , R 12 , MG 1 , MG 2 , X 11 , X 12 and Sp 1 have the meaning given in claim 1, to the use of bimesogenic compounds of formula I in liquid crystal media and in particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention.
Inhibitors of nedd8-activating enzyme
-
Paragraph 0104, (2014/08/20)
The invention relates to an administration unit comprising crystalline form I of {(1 S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate (I-216) hydrochloride salt and to a packaging comprising the administration unit according to the invention.
Chemical Compounds
-
Page/Page column 65-66, (2012/01/15)
The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new sulfonamide Nav1.7 inhibitors of formula (I): or pharmaceutically acceptable salts thereof, wherein Z1, Ra, Rb, R1, R2, R3, R4 and R5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.